Curtain-raiser data keep analysts on edge ahead of Amgen’s big Lumakras/PD-1 combo readout
Will a combination regimen bring Amgen’s big KRAS drug to new heights?
That’s the major question Wall Street found itself mulling in the wake of an abstract drop from the annual World Conference on Lung Cancer. While there were some early data available on Amgen’s Lumakras plus a SHP2 inhibitor being developed by Sanofi and Revolution Medicines, the key readout — from a study pairing Lumakras with a PD-1 drug — is being held back for a late-breaker in August.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,800+ biopharma pros reading Endpoints daily — and it's free.